region stringclasses 1 value | symbol stringlengths 1 5 | exchange stringclasses 8 values | quote_type stringclasses 2 values | currency stringclasses 1 value | name stringlengths 2 84 ⌀ | sector stringclasses 12 values | industry stringclasses 148 values | close float64 0 5.92k ⌀ | volume float64 0 134M ⌀ | market_cap float64 22.4k 2,794B ⌀ | updated_at timestamp[ns] | long_business_summary stringlengths 50 5.19k ⌀ | status stringclasses 1 value | __index_level_0__ int64 0 7.31k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
US | IGA | NYQ | EQUITY | USD | Voya Global Advantage and Premium Opportunity Fund | Financial Services | Asset Management | 8.07 | 60,395 | 127,794,752 | 2023-10-17T13:24:11.996349 | Voya Global Advantage and Premium Opportunity Fund is a closed-ended equity mutual fund launched by Voya Investment Management LLC. The fund is co-managed by Voya Investments, LLC, Voya Investment Management Co. LLC, and NNIP Advisors B.V. It invests in public equity markets across the globe. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in value stocks of companies across all market capitalizations. The fund also invests through index call options on selected indices, equities, and/or exchange-traded funds. It employs fundamental analysis with a bottom-up stock picking approach and a proprietary discounted cash flow valuation model, focusing on such factors as sales, margins, and capital use to create its portfolio. The fund benchmarks the performance of its portfolio against the MSCI World Index. It was formerly known as ING Global Advantage and Premium Opportunity Fund. Voya Global Advantage and Premium Opportunity Fund was formed on July 7, 2005 and is domiciled in the United States. | null | 3,301 |
US | IGBH | PCX | ETF | USD | iShares Interest Rate Hedged Long-Term Corporate Bond ETF | null | null | 23.79 | 6,419 | 62,186,932 | 2023-10-17T13:24:19.523705 | The fund seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in component securities and instruments in the fund’s underlying index and/or bonds included in the underlying index of the underlying fund. | null | 3,302 |
US | IGC | ASE | EQUITY | USD | IGC Pharma, Inc. | Healthcare | Biotechnology | 0.3328 | 73,714 | 20,131,382 | 2023-10-17T13:24:24.992390 | IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. | null | 3,303 |
US | IGD | NYQ | EQUITY | USD | Voya Global Equity Dividend and Premium Opportunity Fund | Financial Services | Asset Management | 4.8 | 222,960 | 387,542,272 | 2023-10-17T13:24:32.709380 | Voya Global Equity Dividend and Premium Opportunity Fund is a closed-ended equity mutual fund launched by Voya Investment Management LLC. The fund is co-managed by Voya Investments, LLC and NNIP Advisors B.V. It invests in public equity markets across the globe. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in dividend paying stocks of companies having a market capitalization of $1 billion or more. The fund also invests through call options on selected indices, individual securities, and/or exchange traded funds. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the MSCI World Index and the Chicago Board Options Exchange BuyWrite Monthly Index. It was formerly known as ING Global Equity Dividend and Premium Opportunity Fund. Voya Global Equity Dividend and Premium Opportunity Fund was formed on March 28, 2005 and is domiciled in the United States. | null | 3,304 |
US | IGE | BTS | ETF | USD | iShares North American Natural Resources ETF | null | null | 41.58 | 170,544 | 600,984,768 | 2023-10-17T13:24:40.099296 | The fund generally invests at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The underlying index measures the performance of U.S.-traded stocks of natural resource-related companies in the U.S. and Canada. | null | 3,305 |
US | IGHG | BTS | ETF | USD | ProShares Investment Grade—Interest Rate Hedged | null | null | 73.802 | 8,556 | 285,874,848 | 2023-10-17T13:24:46.852294 | The index is comprised of (a) long positions in USD-denominated investment grade corporate bonds issued by both U.S. and foreign domiciled companies; and (b) short positions in U.S. Treasury notes or bonds ("Treasury Securities") of, in aggregate, approximate equivalent duration to the investment grade bonds. The fund will invest at least 80% of its total assets in component securities (i.e., securities of the index) and invest at least 80% of its total assets in investment grade bonds. | null | 3,306 |
US | IGI | NYQ | EQUITY | USD | Western Asset Investment Grade Defined Opportunity Trust Inc. | Financial Services | Asset Management | 15.48 | 7,425 | 168,903,360 | 2023-10-17T13:24:53.584483 | Western Asset Investment Grade Defined Opportunity Trust Inc. is a close-ended fixed income mutual fund launched and managed by Legg Mason Partners Fund Advisor, LLC. It is co-managed by Western Asset Management Company, Western Asset Management Company Pte. Ltd, Western Asset Management Company Ltd., and Western Asset Management Company Limited. The fund invests in fixed income markets of the United States. It seeks to invest in securities of companies operating across diversified sectors. The fund primarily invests in investment-grade corporate debt securities with varied maturities. It will liquidate on or about December 2, 2024. The fund conducts in-house research to make its investments. Western Asset Investment Grade Defined Opportunity Trust Inc. was formed on June 26, 2009 and is domiciled in the United States. | null | 3,307 |
US | IGIC | NCM | EQUITY | USD | International General Insurance Holdings Ltd. | Financial Services | Insurance - Diversified | 10.93 | 79,957 | 507,406,144 | 2023-10-17T13:24:59.650446 | International General Insurance Holdings Ltd. provides specialty insurance and reinsurance solutions worldwide. It operates through three segments: Specialty Long-tail, Specialty Short-tail, and Reinsurance. The company underwrites a portfolio of specialty risks, including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency, treaty, and casualty reinsurance. International General Insurance Holdings Ltd. was founded in 2001 and is based in Amman, Jordan. | null | 3,308 |
US | IGLB | PCX | ETF | USD | iShares 10+ Year Investment Grade Corporate Bond ETF | null | null | 46.66 | 522,762 | 1,855,269,248 | 2023-10-17T13:25:06.758979 | The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of investment-grade corporate bonds of both U.S. and non-U.S. issuers that are U.S. dollar-denominated and publicly issued in the U.S. domestic market and have a remaining maturity of greater than or equal to ten years. | null | 3,309 |
US | IGM | PCX | ETF | USD | iShares Expanded Tech Sector ETF | null | null | 390.83 | 31,649 | 3,117,308,928 | 2023-10-17T13:25:12.354254 | The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. A significant portion of the underlying index is represented by securities of companies in the technology industry or sector. It is non-diversified. | null | 3,310 |
US | IGMS | NMS | EQUITY | USD | IGM Biosciences, Inc. | Healthcare | Biotechnology | 4.41 | 366,546 | 259,143,712 | 2023-10-17T13:25:17.939235 | IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. | null | 3,311 |
US | IGN | PCX | ETF | USD | iShares North American Tech-Multimedia Networking ETF | null | null | 57.8868 | 2,431 | 52,536,912 | 2023-10-17T13:25:26.073648 | The fund generally invests at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of U.S.-traded stocks of communication equipment companies in the U.S. The fund is non-diversified. | null | 3,312 |
US | IGPT | PCX | ETF | USD | Invesco Dynamic Software ETF | null | null | 33.1189 | 9,654 | 163,684,160 | 2023-10-17T13:25:33.780831 | The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of securities of companies with significant exposure to technologies or products that contribute to future software development through direct revenue. The fund is non-diversified. | null | 3,313 |
US | IGR | NYQ | EQUITY | USD | CBRE Global Real Estate Income Fund | Financial Services | Asset Management | 4.36 | 533,159 | 620,062,592 | 2023-10-17T13:25:39.207808 | CBRE Clarion Global Real Estate Income Fund specializes in investments in various property types, including office, retail, diversified, apartments, industrials, hotels, healthcare, and storage. It invests in the public equity markets across the developed markets of North America, Europe, Australia, and Asia. The fund seeks to invest in stocks of companies operating across the real estate sector including REITs. It invests in stocks of companies across diversified market capitalizations. The fund employs fundamental analysis to create its portfolio. It conducts in-house research to make its investments. | null | 3,314 |
US | IGRO | BTS | ETF | USD | iShares International Dividend Growth ETF | null | null | 59.2 | 32,862 | 617,647,680 | 2023-10-17T13:25:46.261788 | The fund seeks to track the investment results of the index, which is a dividend dollars weighted index that seeks to measure the performance of international equities selected based on a consistent history of growing dividends. It will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. | null | 3,315 |
US | IGT | NYQ | EQUITY | USD | International Game Technology PLC | Consumer Cyclical | Gambling | 30.58 | 707,599 | 6,183,044,608 | 2023-10-17T13:25:54.188955 | International Game Technology PLC operates and provides gaming technology products and services in North America, Europe, the Middle East, Africa, Asia-Pacific, Latin America, and the Caribbean. It operates in three segments: Global Lottery, Global Gaming, and Digital & Betting. The company designs, sells, operates, and leases a suite of point-of-sale machines that reconciles lottery funds between the retailer and lottery authority; provides online lottery transaction processing systems; produces instant ticket games; and offers printing services, such as instant ticket marketing plans and graphic design, programming, packaging, shipping, and delivery services, as well as iLottery solutions and services. It also designs, develops, assembles, and provides cabinets, games, systems, and software for the gaming market, as well as offers gaming management systems for casino management, customer relationship management, patron management, and server-based gaming. In addition, the company provides video lottery terminals (VLT), VLT central systems, and VLT games. Further, it offers sports betting technology and management services to licensed sports betting operators. Additionally, the company provides digital gaming products and services, including blackjack, roulette, slot games, poker, bingo, and other casino card games; social casino content; and iGaming systems and digital platforms that offer remote game server solution. It processes commercial transactions, such as prepaid cellular telephone recharges, bill payments, e-vouchers and retail-based programs, electronic tax payments, prepaid card recharges, and stamp duty and money transfer services, as well as money transfers. The company was formerly known as GTECH S.p.A. and changed its name to International Game Technology PLC in April 2015. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. International Game Technology PLC is a subsidiary of De Agostini S.p.A. | null | 3,316 |
US | IGTA | NGM | EQUITY | USD | Inception Growth Acquisition Limited | Financial Services | Shell Companies | 10.64 | 471 | 75,671,680 | 2023-10-17T13:26:01.352733 | Inception Growth Acquisition Limited does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on sourcing opportunities in the technology, media and telecom, sports and entertainment, and non-gambling game sectors. Inception Growth Acquisition Limited was incorporated in 2021 and is based in New York, New York. | null | 3,317 |
US | IGV | BTS | ETF | USD | iShares Expanded Tech-Software Sector ETF | null | null | 349.28 | 753,278 | 6,276,216,320 | 2023-10-17T13:26:08.879051 | The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index measures the performance of U.S.-traded stocks from the software industry and select companies from the interactive home entertainment and interactive media and services sub-industries in the U.S. and Canada. The fund is non-diversified. | null | 3,318 |
US | IH | NYQ | EQUITY | USD | iHuman Inc. | Consumer Defensive | Education & Training Services | 2.01 | 37,308 | 109,173,864 | 2024-05-22T17:29:38.036874 | iHuman Inc. provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, iHuman Writing, iHuman Fantastic Friends, and iHuman Readers; bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, bekids Academy, and Gogo Town; and Aha World, an open-ended interactive app that nurtures a desire for discovery. It provides intellectually stimulating materials, including books, interactive materials, and smart devices that develop children's abilities in speaking, critical thinking, independent reading, and creativity. iHuman Inc. was founded in 1996 and is based in Beijing, the People's Republic of China. | null | 3,319 |
US | IHD | NYQ | EQUITY | USD | Voya Emerging Markets High Dividend Equity Fund | Financial Services | Asset Management | 4.83 | 55,847 | 87,973,456 | 2023-10-17T13:26:21.885121 | Voya Emerging Markets High Dividend Equity Fund is a closed-ended equity mutual fund launched by Voya Investment Management LLC. The fund is co-managed by ING Investment Management Advisors B.V. and Voya Investments, LLC. It invests in public equity markets of emerging market countries across the globe. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in dividend paying stocks of companies. The fund also invests through derivatives having economic characteristics similar to the equity securities, such as call options on selected ETF's, and/or international, regional or country indices of equity securities. It employs both fundamental and quantitative analysis with a bottom-up stock selection process to create its portfolio. The fund benchmarks the performance of its portfolio against the MSCI Emerging Markets Index. It was formerly known as ING Emerging Markets High Dividend Equity Fund. Voya Emerging Markets High Dividend Equity Fund was formed on April 26, 2011 and is domiciled in the United States. | null | 3,320 |
US | IHDG | PCX | ETF | USD | WisdomTree International Hedged Quality Dividend Growth Fund | null | null | 38.62 | 361,173 | 1,704,387,328 | 2023-10-17T13:26:29.078696 | The fund will invest at least 80% of its total assets in component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index consists of dividend-paying common stocks with growth characteristics of companies in the industrialized world, excluding Canada and the U.S., while at the same time neutralizing exposure to fluctuations of the value of foreign currencies relative to the USD. It is non-diversified. | null | 3,321 |
US | IHE | PCX | ETF | USD | iShares U.S. Pharmaceuticals ETF | null | null | 179.5619 | 5,035 | 353,912,800 | 2023-10-17T13:26:34.925714 | The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified. | null | 3,322 |
US | IHF | PCX | ETF | USD | iShares U.S. Healthcare Providers ETF | null | null | 252.05 | 23,314 | 873,724,224 | 2023-10-17T13:26:40.741165 | The index measures the performance of the healthcare providers sector of the U.S. equity market, as defined by SPDJI. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified. | null | 3,323 |
US | IHG | NYQ | EQUITY | USD | InterContinental Hotels Group PLC | Consumer Cyclical | Lodging | 72.91 | 104,242 | 12,178,134,016 | 2023-10-17T13:26:47.552190 | InterContinental Hotels Group PLC owns, manages, franchises, and leases hotels in the Americas, Europe, Asia, the Middle East, Africa, and Greater China. The company operates hotels under the Six Senses, Regent, InterContinental Hotels & Resorts, Vignette Collection, Kimpton Hotels & Restaurants, Hotel Indigo, voco, HUALUXE, Crowne Plaza, Iberostar Beachfront Resorts, EVEN, Holiday Inn Express, Holiday Inn, avid, Atwell Suites, Staybridge Suites, Holiday Inn Club Vacations, and Candlewood Suites brand names. It also provides IHG Rewards loyalty program. InterContinental Hotels Group PLC was founded in 1777 and is headquartered in Windsor, the United Kingdom. | null | 3,324 |
US | IHI | PCX | ETF | USD | iShares U.S. Medical Devices ETF | null | null | 45.37 | 1,691,996 | 5,074,343,424 | 2023-10-17T13:26:54.626899 | The fund will invest at least 80% of its assets in the component securities of the index and in investments that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents, as well as in securities not included in the index, but which BFA believes will help the fund track the index. The fund is non-diversified. | null | 3,325 |
US | IHIT | NYQ | EQUITY | USD | Invesco High Income 2023 Target Term Fund | Financial Services | Asset Management | 6.84 | 70,081 | 164,672,992 | 2023-10-17T13:27:02.385305 | Invesco High Income 2023 Target Term Fund is a closed ended fixed income mutual fund launched and managed by Invesco Advisers, Inc. The fund invests in fixed income markets of the United States. It also invests in real estate debt securities including commercial mortgage-backed securities. The fund employs fundamental analysis with bottom-up approach to create its portfolio. It conducts both in-house and external research to make its investments. Invesco High Income 2023 Target Term Fund was formed on November 23, 2016 and is domiciled in the United States. | null | 3,326 |
US | IHRT | NMS | EQUITY | USD | iHeartMedia, Inc. | Communication Services | Broadcasting | 2.63 | 420,296 | 345,899,200 | 2023-10-17T13:27:09.541787 | iHeartMedia, Inc. operates as a media and entertainment company worldwide. The company operates through three segments: Multiplatform Group, Digital Audio Group, and Audio & Media Services Group. The Multiplatform Group segment offers broadcast radio stations, sponsorship, and live and virtual events; and operates Premiere Networks, a national radio network that produces, distributes, or represents syndicated radio programs and services to radio station affiliates. It also delivers real-time traffic flow and incident information, and weather updates, sports, and news. The Digital Audio Group segment provides podcasting, digital sites, newsletters, digital services, and programs; and iHeartRadio, a mobile app and web-based service for radio stations, digital-only stations, custom artist stations, and podcasts. The Audio and Media Services Group segment engages in the media representation business. This segment also provides RCS, a cloud and on-premises broadcast software, such as radio and television automation, music scheduling, newsroom automation, advertising sales management, disaster recovery solutions; and real-time audio recognition technology to radio and television stations, cable channels, record labels, advertisers, and agencies, as well as media streaming and research services. The company was formerly known as CC Media Holdings, Inc. and changed its name to iHeartMedia, Inc. in September 2014. iHeartMedia, Inc. is headquartered in San Antonio, Texas. | null | 3,327 |
US | IHS | NYQ | EQUITY | USD | IHS Holding Limited | Communication Services | Telecom Services | 5.02 | 696,104 | 1,633,949,440 | 2023-10-17T13:27:17.659384 | IHS Holding Limited, together with its subsidiaries, owns, operates, and develops shared communications infrastructure in Nigeria, Sub-Saharan Africa, Latin America, and the Middle East and North Africa. It offers colocation and lease agreement, build-to-suit, inbuilding, small cell, fiber connectivity, and rural telephony solutions. The company serves mobile network operators, internet service providers, security functions, and private corporations. IHS Holding Limited was founded in 2001 and is based in London, the United Kingdom. | null | 3,328 |
US | IHT | ASE | EQUITY | USD | InnSuites Hospitality Trust | Real Estate | REIT - Hotel & Motel | 1.2 | 1,752 | 10,807,452 | 2023-10-17T13:27:25.359234 | InnSuites Hospitality Trust (NYSE American symbol: IHT) first listed on the NYSE in 1971 is headquartered in Phoenix, Arizona is an unincorporated Ohio Business. Trust that owns and manages hotels under the InnSuites Hotels name. IHT qualifies as a Real Estate Investment Trust (REIT) for tax treatment currently taxed as a corporation with the IRS. IHT has paid dividends each year since 1971 currently at $0.2/year. There are approximately 9 million shares of stock outstanding. In addition, there are approximately 3 million RRF Partnership units convertible 1 to 1 into IHT stock. Total shares and units are approximately 12 million. | null | 3,329 |
US | IHTA | NYQ | EQUITY | USD | Invesco High Income 2024 Target Term Fund | null | null | 6.75 | 16,863 | 59,220,268 | 2023-10-17T13:27:31.641667 | null | null | 3,330 |
US | IHY | PCX | ETF | USD | VanEck International High Yield Bond ETF | null | null | 19.315 | 9,932 | 37,297,392 | 2023-10-17T13:27:39.149040 | The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index is comprised of below investment grade bonds issued by corporations located throughout the world (which may include emerging market countries) excluding the United States denominated in Euros, U.S. dollars, Canadian dollars or pound sterling and issued in the major domestic or Eurobond markets. | null | 3,331 |
US | IIF | NYQ | EQUITY | USD | Morgan Stanley India Investment Fund, Inc. | Financial Services | Asset Management | 22.29 | 31,928 | 226,447,552 | 2023-10-17T13:27:44.754473 | Morgan Stanley India Investment Fund, Inc. is a closed ended equity mutual fund launched and managed by Morgan Stanley Investment Management Inc. The fund is co-managed by Morgan Stanley Investment Management Company. It invests in the public equity markets of India. The fund invests in stocks of companies operating across diversified sectors. It benchmarks the performance of its portfolio against the U.S. dollar adjusted BSE National Index. Morgan Stanley India Investment Fund, Inc. was formed on December 22, 1993 and is domiciled in the United States. | null | 3,332 |
US | III | NGM | EQUITY | USD | Information Services Group, Inc. | Technology | Information Technology Services | 4.21 | 46,221 | 210,254,832 | 2023-10-17T13:27:52.267650 | Information Services Group, Inc., together with its subsidiaries, operates as a technology research and advisory company in the Americas, Europe, and the Asia Pacific. The company offers digital transformation services, including automation, cloud, and data analytics; sourcing advisory; managed governance and risk; network carrier; technology strategy and operations design; change management; and market intelligence and technology research and analysis services. It supports private and public sector organizations to transform and optimize their operational environments. The company also provides ISG Digital, a client solution platform that helps clients developing technology, transformation, sourcing, and digital solutions; and ISG Enterprise, a client solution platform that helps clients manage change and optimize operations in areas comprising finance, human resource, and Procure2Pay. In addition, it offers ISG GovernX, a software platform, which provides insights from market and performance data, and automates the management of third-party supplier relationships that comprise contract and project lifecycles, and risk management. The company serves private sector clients operating in the manufacturing, banking and financial services, insurance, health sciences, energy and utilities, and consumer services industries; and public sector clients, including state and local governments, airport and transit authorities, and national and provincial government units. Information Services Group, Inc. was founded in 2006 and is based in Stamford, Connecticut. | null | 3,333 |
US | IIIN | NYQ | EQUITY | USD | Insteel Industries, Inc. | Industrials | Metal Fabrication | 32.23 | 39,184 | 636,806,336 | 2023-10-17T13:27:57.870452 | Insteel Industries, Inc., together with its subsidiaries, manufactures and markets steel wire reinforcing products for concrete construction applications. The company offers prestressed concrete strand (PC strand) and welded wire reinforcement (WWR) products. Its PC strand is a seven-wire strand that is used to impart compression forces into precast concrete elements and structures providing reinforcement for bridges, parking decks, buildings, and other concrete structures. The company's WWR engineered reinforcing product is used in nonresidential and residential construction. It produces a range of WWR products, such as engineered structural mesh, an engineered made-to-order product that is used as the primary reinforcement for concrete elements or structures serving as a reinforcing solution for hot-rolled rebar; concrete pipe reinforcement, an engineered made-to-order product, which is used as the primary reinforcement in concrete pipe, box culverts, and precast manholes for drainage and sewage systems, water treatment facilities, and other related applications; and standard welded wire reinforcement, a secondary reinforcing product for crack control applications in residential and light nonresidential construction, including driveways, sidewalks, and various slab-on-grade applications. The company sells its products through sales representatives to the manufacturers of concrete products, rebar fabricators, distributors, and contractors primarily in the United States, Canada, Mexico, and Central and South America. Insteel Industries, Inc. was founded in 1953 and is headquartered in Mount Airy, North Carolina. | null | 3,334 |
US | IIIV | NMS | EQUITY | USD | i3 Verticals, Inc. | Technology | Software - Infrastructure | 19.65 | 128,896 | 688,139,648 | 2023-10-17T13:28:05.442821 | i3 Verticals, Inc. provides integrated payment and software solutions to small- and medium-sized businesses and organizations in education, non-profit, public sector, and healthcare markets in the United States. It operates in two segments, Merchant Services, and Proprietary Software and Payments. The company offers payment processing services that enables clients to accept electronic payments, facilitating the exchange of funds and transaction data between clients, financial institutions, and payment networks. The company also licenses software; and provides ongoing support, and other point of sale-related solutions. It offers its solutions to clients through direct sales force; distribution partners, including independent software vendors, value-added resellers, and independent sales organizations; and referral partners, such as financial institutions, trade associations, chambers of commerce, and card issuers. The company was founded in 2012 and is headquartered in Nashville, Tennessee. | null | 3,335 |
US | IIM | NYQ | EQUITY | USD | Invesco Value Municipal Income Trust | Financial Services | Asset Management | 10.5 | 101,295 | 490,923,424 | 2023-10-17T13:28:13.544445 | Invesco Value Municipal Income Trust is a closed-ended fixed income mutual fund launched by Invesco Ltd. The fund is co-managed by Invesco Advisers, Inc., INVESCO Asset Management (Japan) Limited, INVESCO Asset Management Deutschland GmbH, INVESCO Asset Management Limited, Invesco Canada Ltd., Invesco Hong Kong Limited, and INVESCO Senior Secured Management, Inc. It invests in the fixed income markets of the United States. The fund primarily invests in investment grade municipal securities which include municipal bonds, municipal notes, municipal commercial paper, and lease obligations. It employs fundamental analysis with bottom-up security selection approach to create its portfolio. The fund was previously known as Invesco Insured Municipal Income Trust. Invesco Value Municipal Income Trust was formed on February 26, 1993 and is domiciled in the United States. | null | 3,336 |
US | IINN | NCM | EQUITY | USD | Inspira Technologies Oxy B.H.N. Ltd. | Healthcare | Medical Devices | 1.32 | 14,019 | 16,224,830 | 2023-10-17T13:28:19.866167 | Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel. | null | 3,337 |
US | IIPR | NYQ | EQUITY | USD | Innovative Industrial Properties, Inc. | Real Estate | REIT - Industrial | 75.48 | 201,494 | 2,177,025,536 | 2023-10-17T13:28:26.403425 | Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized properties leased to experienced, state-licensed operators for their regulated cannabis facilities. Innovative Industrial Properties, Inc. has elected to be taxed as a real estate investment trust, commencing with the year ended December 31, 2017. | null | 3,338 |
US | IJH | PCX | ETF | USD | iShares Core S&P Mid-Cap ETF | null | null | 243.58 | 1,385,961 | 70,754,721,792 | 2023-10-17T13:28:34.746534 | The index measures the performance of the mid-capitalization sector of the U.S. equity market, as determined by SPDJI. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. | null | 3,339 |
US | IJJ | PCX | ETF | USD | iShares S&P Mid-Cap 400 Value ETF | null | null | 97.84 | 138,255 | 6,612,985,856 | 2023-10-17T13:28:42.349798 | The index measures the performance of the mid-capitalization value sector of the U.S. equity market. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. | null | 3,340 |
US | IJK | PCX | ETF | USD | iShares S&P Mid-Cap 400 Growth ETF | null | null | 71.06 | 232,210 | 7,384,672,256 | 2023-10-17T13:28:50.588321 | The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. | null | 3,341 |
US | IJR | PCX | ETF | USD | iShares Core S&P Small-Cap ETF | null | null | 91.22 | 3,747,148 | 66,490,216,448 | 2023-10-17T13:28:57.957524 | The index measures the performance of the small-capitalization sector of the U.S. equity market, as determined by SPDJI. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. | null | 3,342 |
US | IJS | PCX | ETF | USD | iShares S&P Small-Cap 600 Value ETF | null | null | 85.57 | 331,437 | 6,306,158,592 | 2023-10-17T13:29:05.592641 | The index measures the performance of the small-capitalization value sector of the U.S. equity market. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. | null | 3,343 |
US | IKNA | NGM | EQUITY | USD | Ikena Oncology, Inc. | Healthcare | Biotechnology | 4.21 | 61,072 | 186,736,736 | 2023-10-17T13:29:12.225056 | Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. | null | 3,344 |
US | IKT | NCM | EQUITY | USD | Inhibikase Therapeutics, Inc. | Healthcare | Biotechnology | 0.95 | 211,421 | 5,331,750 | 2023-10-17T13:29:20.285829 | Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. | null | 3,345 |
US | ILAG | NCM | EQUITY | USD | Intelligent Living Application Group Inc. | Industrials | Building Products & Equipment | 0.85 | 6,001 | 16,073,400 | 2023-10-17T13:29:28.363241 | Intelligent Living Application Group Inc., through its subsidiaries, manufactures and sells mechanical locksets to customers in the United States and Canada. Its mechanical locksets consist of deadbolts, entry locksets, privacy locksets, and passage locksets as well as storerooms locks. The company offers locksets for outdoors comprising main entrances and gates, and indoor uses. Intelligent Living Application Group Inc. was founded in 1981 and is headquartered in Kwai Chung, Hong Kong. | null | 3,346 |
US | ILCB | PCX | ETF | USD | iShares Morningstar U.S. Equity ETF | null | null | 59.47 | 12,260 | 745,767,296 | 2023-10-17T13:29:36.377908 | The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of U.S. stocks issued by large-mid capitalization companies that have exhibited similar “growth” and “value” characteristics, as determined by Morningstar, Inc.’s proprietary index methodology. | null | 3,347 |
US | ILCG | PCX | ETF | USD | iShares Morningstar Growth ETF | null | null | 60.83 | 28,524 | 1,663,438,464 | 2023-10-17T13:29:42.336544 | The fund will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of U.S. stocks issued by large-mid capitalization companies that have exhibited above-average “growth” characteristics. It is non-diversified. | null | 3,348 |
US | ILCV | PCX | ETF | USD | iShares Morningstar Value ETF | null | null | 64.47 | 32,956 | 818,906,112 | 2023-10-17T13:29:48.404633 | The fund will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of U.S. stocks issued by large-mid capitalization companies that have exhibited above-average “value” characteristics as determined by Morningstar’s proprietary index methodology. | null | 3,349 |
US | ILF | PCX | ETF | USD | iShares Latin America 40 ETF | null | null | 24.95 | 678,641 | 1,411,757,312 | 2023-10-17T13:29:55.085775 | The fund generally invests at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. It seeks to track the investment results of the S&P Latin America 40TM (the "underlying index"), which is composed of selected equities trading on the exchanges of five Latin American countries. The fund is non-diversified. | null | 3,350 |
US | ILLM | NCM | EQUITY | USD | illumin Holdings Inc. | Communication Services | Advertising Agencies | 1.67 | 70,531 | 84,095,608 | 2023-10-17T13:30:00.714593 | illumin Holdings Inc., a technology company, provides digital media solutions in the United States, Canada, Europe, Latin America, and internationally. The company offers a programmatic marketing platform that enables advertisers to connect with their audiences across online display, video, social, and mobile campaigns. Its platform also allows advertisers to manage their purchasing of online display advertising in real-time using programmatic ad buying. In addition, the company offers illumin, an advertising automation technology that provides planning, media buying, and omnichannel intelligence; and allows advertisers to map their consumer journey playbooks across screens and execute in real-time using programmatic technology. It serves Fortune 500 enterprises and small to mid-sized businesses. The company was formerly known as AcuityAds Holdings Inc. and changed its name to illumin Holdings Inc. in June 2023. illumin Holdings Inc. is headquartered in Toronto, Canada. | null | 3,351 |
US | ILMN | NMS | EQUITY | USD | Illumina, Inc. | Healthcare | Diagnostics & Research | 129.11 | 1,088 | 20,797,454,336 | 2023-10-17T13:30:06.130775 | Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California. | null | 3,352 |
US | ILPT | NMS | EQUITY | USD | Industrial Logistics Properties Trust | Real Estate | REIT - Industrial | 2.57 | 4,316 | 167,527,088 | 2023-10-17T13:30:12.851131 | ILPT is a real estate investment trust focused on owning and leasing high quality distribution and logistics properties that serve the growing needs of e-commerce. As of June 30, 2023, ILPT's portfolio consisted of 413 properties containing approximately 60.0 million rentable square feet located in 39 states. Approximately 77% of ILPT's annualized rental revenues as of June 30, 2023 are derived from investment grade tenants, tenants that are subsidiaries of investment grade rated entities or Hawaii land leases. ILPT is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with approximately $36 billion in assets under management as of June 30, 2023, and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate. ILPT is headquartered in Newton, MA. | null | 3,353 |
US | ILTB | PCX | ETF | USD | iShares Core 10+ Year USD Bond ETF | null | null | 46.6619 | 982 | 502,415,136 | 2023-10-17T13:30:19.583666 | The underlying index measures the performance of U.S. dollar-denominated taxable bonds that are rated either investment-grade or high yield with remaining maturities greater than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the underlying index. | null | 3,354 |
US | IMAB | NGM | EQUITY | USD | I-Mab | Healthcare | Biotechnology | 1.3 | 6,240 | 107,410,280 | 2023-10-17T13:30:26.567133 | I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. | null | 3,355 |
US | IMAQ | NCM | EQUITY | USD | International Media Acquisition Corp. | Financial Services | Shell Companies | 11.24 | 20 | 96,020,632 | 2023-10-17T13:30:32.374943 | International Media Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the media and entertainment sector. International Media Acquisition Corp. was incorporated in 2021 and is based in North Brunswick, New Jersey. | null | 3,356 |
US | IMAX | NYQ | EQUITY | USD | IMAX Corporation | Communication Services | Entertainment | 17.77 | 4,003 | 960,221,376 | 2023-10-17T13:30:39.799024 | IMAX Corporation, together with its subsidiaries, operates as a technology platform for entertainment and events worldwide. The company operates through three segments: IMAX Technology Network; IMAX Technology Sales and Maintenance; and Film Distribution and Post-Production. The company offers IMAX DMR, a proprietary technology that digitally remasters films and other content into IMAX formats for distribution to the IMAX network; IMAX Enhanced that provides end-to-end technology across streaming content and entertainment devices at home; and SSIMWAVE, an AI-driven video quality solutions for media and entertainment companies. It also offers preventative and emergency maintenance services to the IMAX network; film post-production services; and IMAX film and digital cameras to content creators. In addition, the company engages in the distribution of large-format documentary films to institutional theaters, as well as live performances and interactive events with artists and creators; after-market sales of IMAX System parts and 3D glasses; operation of IMAX theater; provision of management services to three other theaters, as well as production advice and technical assistance to documentary and Hollywood filmmakers; and rental of Company's proprietary 2D and 3D large-format film. The company markets its theater systems through a direct sales force and marketing staff to science and natural history museums, zoos, aquaria, and other educational and cultural centers, as well as theme parks, private home theaters, tourist destination sites, fairs, and expositions. It offers its services under the IMAX, IMAX 3D, Experience It In IMAX, The IMAX Experience, DMR, Filmed For IMAXTM, IMAX LiveTM, IMAX Enhanced, and SSIMWAVE. The company operates a network of IMAX systems comprising commercial multiplexes, commercial destinations, and institutional facilities in 87 countries and territories. IMAX Corporation was founded in 1967 and is headquartered in Mississauga, Canada. | null | 3,357 |
US | IMCB | PCX | ETF | USD | iShares Morningstar Mid-Cap ETF | null | null | 59.2612 | 16,300 | 719,807,680 | 2023-10-17T13:30:45.600426 | The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of U.S. stocks issued by mid-capitalization companies that have exhibited both “growth” and “value” characteristics as determined by Morningstar, Inc.’s (“Morningstar” or the “index provider”) proprietary index methodology. | null | 3,358 |
US | IMCC | NCM | EQUITY | USD | IM Cannabis Corp. | Healthcare | Drug Manufacturers - Specialty & Generic | 0.6291 | 45,182 | 8,343,425 | 2023-10-17T13:30:53.233231 | IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel. | null | 3,359 |
US | IMCG | PCX | ETF | USD | iShares Morningstar Mid-Cap Growth ETF | null | null | 57.65 | 5,624 | 1,516,747,648 | 2023-10-17T13:30:59.262906 | The fund will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of U.S. stocks issued by mid-capitalization companies that have exhibited above-average "growth" characteristics as determined by Morningstar, Inc.'s proprietary index methodology. | null | 3,360 |
US | IMCR | NMS | EQUITY | USD | Immunocore Holdings plc | Healthcare | Biotechnology | 50.54 | 1,674 | 2,472,025,088 | 2023-10-17T13:31:04.570777 | Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. | null | 3,361 |
US | IMGN | NMS | EQUITY | USD | ImmunoGen, Inc. | Healthcare | Biotechnology | 14.64 | 17,165 | 3,681,867,008 | 2023-10-17T13:31:11.338327 | ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. | null | 3,362 |
US | IMKTA | NMS | EQUITY | USD | Ingles Markets, Incorporated | Consumer Defensive | Grocery Stores | 77.05 | 142 | 1,494,289,408 | 2023-10-17T13:31:18.472172 | Ingles Markets, Incorporated operates a chain of supermarkets in the southeast United States. It offers food products, including grocery, meat and dairy products, produce, frozen foods, and other perishables; and non-food products, which include fuel centers, pharmacies, health and beauty care products, and general merchandise, as well as private label items. The company also owns and operates a milk processing and packaging plant that supplies organic milk, fruit juices, and bottled water products to other retailers, food service distributors, and grocery warehouses. In addition, it provides home meal replacement items, delicatessens, bakeries, floral departments, and greeting cards, as well as broad selections of local organic, beverage, and health-related items. It operates under the brand names Ingles, Sav-Mor, as well as pharmacies and fuel stations. Ingles Markets, Incorporated was founded in 1963 and is headquartered in Asheville, North Carolina. | null | 3,363 |
US | IMMP | NGM | EQUITY | USD | Immutep Limited | Healthcare | Biotechnology | 1.82 | 1,029 | 164,338,320 | 2023-10-17T13:31:24.677954 | Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia. | null | 3,364 |
US | IMMR | NMS | EQUITY | USD | Immersion Corporation | Technology | Software - Application | 6.74 | 2,009 | 216,018,048 | 2023-10-17T13:31:32.753560 | Immersion Corporation, together with its subsidiaries, creates, designs, develop, and licenses haptic technologies that allow people to use their sense of touch to engage with and experience various digital products in North America, Europe, and Asia. The company provides technology, patent, and combined licenses. It also provides software development kits (SDKs) comprising tools, integration software, and effect libraries that allow for the design, encoding, and playback of tactile effects. In addition, the company offers reference designs and reference technology, engineering and integration services, and software and firmware services. It serves mobile communications, wearables, and consumer electronics; gaming and virtual reality (VR); automotive; and other markets. Immersion Corporation was incorporated in 1993 and is headquartered in Aventura, Florida. | null | 3,365 |
US | IMMX | NCM | EQUITY | USD | Immix Biopharma, Inc. | Healthcare | Biotechnology | 2.97 | 3,846 | 61,200,868 | 2023-10-17T13:31:38.696280 | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California. | null | 3,366 |
US | IMNM | NCM | EQUITY | USD | Immunome, Inc. | Healthcare | Biotechnology | 8.92 | 233 | 381,991,296 | 2023-10-17T13:31:46.749035 | Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. | null | 3,367 |
US | IMNN | NCM | EQUITY | USD | Imunon, Inc. | Healthcare | Biotechnology | 0.98 | 1,534 | 9,180,503 | 2023-10-17T13:31:52.169170 | Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey. | null | 3,368 |
US | IMO | ASE | EQUITY | USD | Imperial Oil Limited | Energy | Oil & Gas Integrated | 61.03 | 4,149 | 35,580,760,064 | 2023-10-17T13:31:58.086787 | Imperial Oil Limited engages in exploration, production, and sale of crude oil and natural gas in Canada. The company operates through three segments: Upstream, Downstream and Chemical segments. The Upstream segment explores for, and produces crude oil, natural gas, synthetic crude oil, and bitumen. The Downstream segment is involved in the transportation and refining of crude oil, blending of refined products, and the distribution and marketing of refined products. It also transports crude oil production and third-party crude oil to refineries by contracted pipelines, common carrier pipelines, and rail; owns and operates refineries; maintains a distribution system to move petroleum products to market by pipeline, tanker, rail, and road transport; owns and operates fuel terminals, natural gas liquids, and products pipelines in Alberta, Manitoba, and Ontario; markets petroleum products under the Esso and Mobil brands; and sells petroleum products, including fuel, asphalt, and lubricants for industrial and transportation customers, independent marketers, and resellers, as well as other refiners serving the agriculture, residential heating, and commercial markets through branded fuel and lubricant resellers. The Chemical segment manufactures and markets various benzene, aromatic and aliphatic solvents, plasticizer intermediates, and polyethylene resin; and markets refinery grade propylene. The company was incorporated in 1880 and is headquartered in Calgary, Canada. Imperial Oil Limited is a subsidiary of Exxon Mobil Corporation. | null | 3,369 |
US | IMOS | NMS | EQUITY | USD | ChipMOS TECHNOLOGIES INC. | Technology | Semiconductors | 23.86 | 450 | 871,537,152 | 2023-10-17T13:32:04.962019 | ChipMOS TECHNOLOGIES INC. researches, develops, manufactures, and sells high-integration and high-precision integrated circuits, and related assembly and testing services in the People's Republic of China, Japan, Singapore, and internationally. It operates through Testing; Assembly; Testing and Assembly for LCD, OLED and Other Display Panel Driver Semiconductors; Bumping; and Others segments. The company provides a range of back-end assembly and testing services, including engineering test, wafer probing, and final test of memory and logic/mixed-signal semiconductors, as well as leadframe-based and organic substrate-based package assembly services for memory and logic/mixed-signal semiconductors; and gold bumping, reel to reel assembly, and test services for LCD, OLED, and other panel display driver semiconductors. Its semiconductors are used in personal computers; graphics applications, such as game consoles; communications equipment; mobile products comprising cellular handsets, tablets, and consumer electronic products; and automotive/industry and display applications, such as display panels. ChipMOS TECHNOLOGIES INC. was incorporated in 1997 and is headquartered in Hsinchu, Taiwan. | null | 3,370 |
US | IMPL | NGM | EQUITY | USD | Impel Pharmaceuticals Inc. | Healthcare | Biotechnology | 0.3501 | 4,200 | 8,312,150 | 2023-10-17T13:32:11.383673 | Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. | null | 3,371 |
US | IMPP | NCM | EQUITY | USD | Imperial Petroleum Inc. | Energy | Oil & Gas Midstream | 1.92 | 34,046 | 49,621,448 | 2023-10-17T13:32:19.488663 | Imperial Petroleum Inc. provides international seaborne transportation services to oil producers, refineries, and commodities traders. It carries refined petroleum products, such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals, crude oils, iron ore, coal and grains, and minor bulks, such as bauxite, phosphate, and fertilizers. As of March 28, 2023, the company owned and operated a fleet of five medium range refined petroleum product tankers; one Aframax tanker; two suezmax tankers; and four handysize drybulk carriers with a total capacity of 807,804 deadweight tons. The company was incorporated in 2021 and is based in Athens, Greece. | null | 3,372 |
US | IMRN | NCM | EQUITY | USD | Immuron Limited | Healthcare | Biotechnology | 1.72 | 467 | 10,849,230 | 2023-10-17T13:32:27.202487 | Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia. | null | 3,373 |
US | IMRX | NGM | EQUITY | USD | Immuneering Corporation | Healthcare | Biotechnology | 6 | 38 | 176,169,280 | 2023-10-17T13:32:34.144875 | Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. | null | 3,374 |
US | IMTB | PCX | ETF | USD | iShares Core 5-10 Year USD Bond ETF | null | null | 40.8122 | 2,445 | 185,002,160 | 2023-10-17T13:32:42.170613 | The fund will invest at least 80% of its assets in the component securities of the index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index. The index measures the performance of U.S. dollar-denominated taxable bonds that are rated either investment-grade or high yield with remaining effective maturities between five and ten years. | null | 3,375 |
US | IMTE | NCM | EQUITY | USD | Integrated Media Technology Limited | Technology | Electronic Components | 1.88 | 6,177 | 37,309,124 | 2023-10-17T13:32:47.871758 | Integrated Media Technology Limited engages in the manufacture and sale of laminated switchable glass, nano-coated plate for filters, air purifiers, and Internet of Things (IoT) products. It also engages in the sale of electronic glass; operation of Ouction, a non-fungible token trading marketplace; and provision of halal certification and distribution of halal products. The company was formerly known as China Integrated Media Corporation Limited and changed its name to Integrated Media Technology Limited in October 2016. Integrated Media Technology Limited was incorporated in 2008 and is headquartered in Shah Alam, Malaysia. | null | 3,376 |
US | IMTM | PCX | ETF | USD | iShares MSCI Intl Momentum Factor ETF | null | null | 31.43 | 182,616 | 1,456,494,080 | 2023-10-17T13:32:54.170570 | The fund will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index. The index consists of stocks exhibiting relatively higher momentum characteristics than the traditional market capitalization-weighted parent index, the MSCI World ex USA Index. | null | 3,377 |
US | IMTX | NCM | EQUITY | USD | Immatics N.V. | Healthcare | Biotechnology | 9.87 | 1,506 | 791,114,368 | 2023-10-17T13:33:01.284991 | Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. | null | 3,378 |
US | IMUX | NMS | EQUITY | USD | Immunic, Inc. | Healthcare | Biotechnology | 1.23 | 48,405 | 55,298,296 | 2023-10-17T13:33:08.336164 | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York. | null | 3,379 |
US | IMVT | NMS | EQUITY | USD | Immunovant, Inc. | Healthcare | Biotechnology | 37.75 | 54,964 | 5,624,198,144 | 2023-10-17T13:33:15.822472 | Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. | null | 3,380 |
US | IMXI | NCM | EQUITY | USD | International Money Express, Inc. | Technology | Software - Infrastructure | 16.6 | 2,255 | 587,235,392 | 2023-10-17T13:33:21.773333 | International Money Express, Inc., through its subsidiary, operates as a money remittance services company in the United States, Latin America, Mexico, Central and South America, the Caribbean, Africa, and Asia. The company offers remittance services, which include a suite of ancillary financial processing solutions and payment services; and online payment options, pre-paid debit cards, and direct deposit payroll cards. It provides services through sending and paying agents and company-operated stores, as well as through online and Internet-enabled mobile devices. International Money Express, Inc. is headquartered in Miami, Florida. | null | 3,381 |
US | INAB | NGM | EQUITY | USD | IN8bio, Inc. | Healthcare | Biotechnology | 0.9348 | 1,729 | 28,393,590 | 2023-10-17T13:33:29.863197 | IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. | null | 3,382 |
US | INBK | NMS | EQUITY | USD | First Internet Bancorp | Financial Services | Banks - Regional | 16.98 | 149 | 146,975,536 | 2023-10-17T13:33:36.126248 | First Internet Bancorp operates as the bank holding company for First Internet Bank of Indiana that provides commercial, small business, consumer, and municipal products and services to individuals and commercial customers in the United States. The company accepts non-interest bearing and interest-bearing demand deposit, savings, money market, commercial and brokered deposit accounts, as well as certificates of deposit. It also offers commercial and industrial, owner-occupied and investor commercial real estate, construction, residential mortgage, home equity line of credit and home improvement, small installment, term, and other consumer loans, as well as single tenant lease financing, and public and healthcare finance; franchise finance; and small business lending. In addition, the company is involved in the purchase, manage, service, and safekeeping of municipal securities; and provision of municipal finance lending and leasing products to government entities In addition, it offers corporate credit card and treasury management services. First Internet Bancorp was founded in 1999 and is headquartered in Fishers, Indiana. | null | 3,383 |
US | INBS | NCM | EQUITY | USD | Intelligent Bio Solutions Inc. | Healthcare | Medical Devices | 0.3 | 46,384 | 1,413,981 | 2023-10-17T13:33:41.906652 | Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. | null | 3,384 |
US | INBX | NGM | EQUITY | USD | Inhibrx, Inc. | Healthcare | Biotechnology | 18.2 | 1,634 | 808,298,368 | 2023-10-17T13:33:47.908382 | Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California. | null | 3,385 |
US | INCO | PCX | ETF | USD | Columbia India Consumer ETF | null | null | 54.08 | 1,088 | 119,757,824 | 2023-10-17T13:33:55.924467 | The fund will invest at least 80% of its net assets in Indian consumer companies included in the index and the advisor generally expects to be substantially invested at such times, with at least 95% of its net assets invested in these securities. The index is a maximum 30-stock free-float adjusted market capitalization-weighted index designed to measure the market performance of companies in the consumer industry in India, as defined by Indxx's proprietary methodology. It is non-diversified. | null | 3,386 |
US | INCR | NGM | EQUITY | USD | InterCure Ltd. | Healthcare | Drug Manufacturers - Specialty & Generic | 1.3 | 590 | 58,333,056 | 2023-10-17T13:34:01.295114 | InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel. | null | 3,387 |
US | INCY | NMS | EQUITY | USD | Incyte Corporation | Healthcare | Biotechnology | 57.63 | 10,900 | 12,959,009,792 | 2023-10-17T13:34:09.335262 | Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. | null | 3,388 |
US | INDA | BTS | ETF | USD | iShares MSCI India ETF | null | null | 44.76 | 54,242 | 6,041,856,512 | 2023-10-17T13:34:16.088146 | The fund generally will collectively invest at least 80% of the fund's assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index measures the performance of equity securities of companies whose market capitalization, as calculated by the index provider, represents the large- and mid-capitalization segments of the Indian securities market. The fund is non-diversified. | null | 3,389 |
US | INDB | NMS | EQUITY | USD | Independent Bank Corp. | Financial Services | Banks - Regional | 48.38 | 2,391 | 2,144,539,136 | 2023-10-17T13:34:24.167161 | Independent Bank Corp. operates as the bank holding company for Rockland Trust Company that provides commercial banking products and services to individuals and small-to-medium sized businesses primarily in Massachusetts. It accepts interest checking, money market, and savings accounts, as well as demand deposits and time certificates of deposit. The company also offers commercial and industrial, commercial real estate and construction, small business, and consumer real estate. In addition, it provides investment management and trust services to individuals, institutions, small businesses, and charitable institutions; Internet and mobile banking services, as well as estate settlement, financial planning, tax services, and other services; automated teller machine and debit cards; and mutual fund and unit investment trust shares, general securities, fixed and variable annuities, and life insurance products, as well as advisory platforms. The company was founded in 1907 and is headquartered in Rockland, Massachusetts. | null | 3,390 |
US | INDI | NCM | EQUITY | USD | indie Semiconductor, Inc. | Technology | Semiconductor Equipment & Materials | 5.77 | 106,274 | 891,172,672 | 2023-10-17T13:34:31.762865 | indie Semiconductor, Inc. provides automotive semiconductors and software solutions for advanced driver assistance systems, autonomous vehicle, in-cabin, connected car, and electrification applications in the United States, South America, rest of North America, Greater China, rest of Asia Pacific, and Europe. It offers ultrasonic sensors for parking assist and systems; radar sensors for audio assistance and reverse information; front cameras for vehicle detection, collision avoidance, and sign reading; and side/inside cameras for blind spot and lane change assist, and driver behavior monitoring. The company also provides LiDAR for distance, speed, and obstacle detection, collision avoidance, and emergency brake system; and long range RADAR for audio assistance, obstacle detection, and ACC stop and go. In addition, it designs and manufactures photonic components on various technology platforms, including fiber Bragg gratings, low-noise lasers, athermal and tunable packaging, photonic integration, and low-noise and high-speed electronics. The company was founded in 2007 and is headquartered in Aliso Viejo, California. | null | 3,391 |
US | INDL | PCX | ETF | USD | Direxion Daily MSCI India Bull 2X Shares | null | null | 48.2509 | 384 | 62,236,648 | 2023-10-17T13:34:37.657390 | The index is designed to measure the performance of the large- and mid-capitalization segments of the Indian equity market, covering approximately 85% of the Indian equity universe. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, ETFs that track the index, securities of the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index which provide returns consistent with the objective. It is non-diversified. | null | 3,392 |
US | INDO | ASE | EQUITY | USD | Indonesia Energy Corporation Limited | Energy | Oil & Gas E&P | 3.85 | 4,329 | 38,963,184 | 2023-10-17T13:34:46.055336 | Indonesia Energy Corporation Limited operates as an oil and gas exploration and production company in Indonesia. The company holds interests in the Kruh Block, a producing block covering an area of 258 square kilometers with net crude oil proved reserves of 2.06 million barrels located to the northwest of Pendopo, Pali, South Sumatra; and the Citarum Block, an exploration block covering an area of 3,924.67 square kilometers located onshore in West Java. The company was incorporated in 2018 and is headquartered in Jakarta, Indonesia. Indonesia Energy Corporation Limited is a subsidiary of Maderic Holding Limited. | null | 3,393 |
US | INDP | NCM | EQUITY | USD | Indaptus Therapeutics, Inc. | Healthcare | Biotechnology | 2.45 | 62 | 21,590,698 | 2023-10-17T13:34:52.707438 | Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. | null | 3,394 |
US | INDV | NMS | EQUITY | USD | Indivior PLC | Healthcare | Drug Manufacturers - Specialty & Generic | 19.4 | 5,727 | 2,765,372,672 | 2023-10-17T13:34:58.616684 | Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. | null | 3,395 |
US | INFA | NYQ | EQUITY | USD | Informatica Inc. | Technology | Software - Infrastructure | 21.24 | 9,629 | 6,059,499,520 | 2023-10-17T13:35:06.018144 | Informatica Inc. develops an artificial intelligence-powered platform that connects, manages, and unifies data across multi-cloud, hybrid systems at enterprise scale in the United States. The company's platform includes a suite of interoperable data management products, including data integration products to ingest, transform, and integrate data; API and application integration products that enable users to create and manage APIs and integration processes for app-to-app synchronization, business process orchestration, B2B partner management, application development, and API management; data quality products to profile, cleanse, standardize, and enrich data to deliver accurate, complete, and consistent data; and master data management products to create an authoritative single source of truth of business-critical data. Its platform also includes customer and business 360 application that allow business analysts to create comprehensive 360-degree views of business data domains like customer, product, supplier, reference, and finance with simplified business user experiences; data catalog products that enables customers to quickly find, access, and understand enterprise data using a simple Google-like search experience; and governance and privacy products that help users govern data, enable compliance with industry and corporate policies. The company also offers maintenance and professional services. Informatica Inc. was founded in 1993 and is headquartered in Redwood City, California. | null | 3,396 |
US | INFI | PNK | EQUITY | USD | Infinity Pharmaceuticals, Inc. | Healthcare | Biotechnology | 0.008 | 2,476,982 | 726,088 | 2023-10-17T13:35:14.216112 | Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. | null | 3,397 |
US | INFN | NMS | EQUITY | USD | Infinera Corporation | Technology | Communication Equipment | 3.58 | 13,271 | 791,964,736 | 2023-10-17T13:35:22.073640 | Infinera Corporation provides optical transport networking equipment, software, and services worldwide. The company's product portfolio includes Infinera Groove series for modular and sled-based platforms to support a various transport network applications; Infinera 7300 series, an SDN-ready coherent optical transport system; Infinera FlexILS open optical line system that connects various Infinera and third-party terminal equipment platforms over long-distance fiber optic cable providing switching, multiplexing, amplification, and management channels; and Infinera 7090 and 7100 series for transport platforms. It also offers Infinera XTM series, a packet-optical transport platform that enables metro connectivity solutions; Infinera XTC series, a multi-terabit packet optical transport platforms that integrates digital OTN switching and optical DWDM transmission; Infinera mTera series, a network transport solution; and Infinera XT series, a platform that is designed to power cloud scale network services over metro, DCI, long-haul, and subsea networks. In addition, the company provides Infinera Cloud Xpress Family that is designed to meet the needs of internet content providers (ICPs), communication service providers, internet exchange service providers, enterprises, and other large-scale data center operators; and ICE-X Coherent Pluggable Optics. It also offers Infinera Transcend software suite; and system software and customer support services. The company serves telecommunications service providers, ICPs, cable providers, wholesale carriers, research and education institutions, large enterprises, and government entities. It markets and sells its products and related support services primarily through its direct sales force. The company was formerly known as Zepton Networks. Infinera Corporation was incorporated in 2000 and is headquartered in San Jose, California. | null | 3,398 |
US | INFU | ASE | EQUITY | USD | InfuSystem Holdings, Inc. | Healthcare | Medical Instruments & Supplies | 9.81 | 21,259 | 206,547,600 | 2023-10-17T13:35:28.076366 | InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan. | null | 3,399 |
US | INFY | NYQ | EQUITY | USD | Infosys Limited | Technology | Information Technology Services | 17.21 | 180,518 | 71,289,208,832 | 2023-10-17T13:35:35.641373 | Infosys Limited, together with its subsidiaries, provides consulting, technology, outsourcing, and next-generation digital services in North America, Europe, India, and internationally. It provides application management and application development services, independent validation solutions, product engineering and management, infrastructure management services, traditional enterprise application implementation, support, and integration services. The company's products and platforms include Finacle, a core banking solution; Edge suite of products; Panaya platform, Infosys Equinox, Infosys Helix, Infosys Applied AI, Infosys Cortex, and Stater digital platforms; and Infosys McCamish, an insurance platform. It serves enterprises in the financial services and insurance, manufacturing, retail, consumer packaged goods, logistics, energy, utilities, resources, services, communications, telecom OEM, media, hi-tech, and life sciences and healthcare industries. The company has a collaboration with Microsoft to accelerate and democratize industry-wide adoption of generative AI. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Limited in June 2011. Infosys Limited was incorporated in 1981 and is headquartered in Bengaluru, India. | null | 3,400 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.